144
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients

, , , , , , , , , , , , , , , & show all
Pages 478-482 | Received 18 Jun 2022, Accepted 03 Nov 2022, Published online: 24 Nov 2022
 

Acknowledgments

Obinutuzumab was supplied by Roche and Bendamustine was provided by Mundipharma during the trial.

Disclosure statement

Nadine Kutsch Grants: Gilead, AstraZeneca. Payment for lectures including service on speakers bureaus: AstraZeneca, Roche. Honoraria: AstraZeneca, BMS. Travel support from AstraZeneca, Celgene, Gilead, Janssen.

Emily Eva Holmes no conflict of interest

Sandra Robrecht Honoraria: AstraZeneca

Gudrun Schüler no conflict of interest

Ursula Vehling-Kaiser no conflict of interest

Thomas Decker Consultancy and payment for lectures including service on speakers bureaus: Novartis

Sigrun Müller-Hagen no conflict of interest

Karin Heinisch no conflict of interest

Sebastian Böttcher Honoraria: AbbVie, AstraZeneca, Janssen, Roche, Sanof. Consulting or Advisory Role: AbbVie, AstraZeneca, Janssen, Roche, Sanofi. Research Funding: Janssen

Matthias Ritgen Consulting fee or Honorarium: AbbVie, AstraZeneca, Janssen, Roche. Travel support: AbbVie, AstraZeneca, Janssen, Roche. Patents: EuroFlow MRD Diagnostics

Karl-Anton Kreuzer Consultancy: Mundipharma, Roche. Grants Mundipharma, Roche. Payment for lectures including service on speakers bureaus Mundipharma, Roche

Stephan Stilgenbauer fees for consulting, drug/equipment supplied by the entity, travel paid by the entity, writing assistance: AbbVie, AstraZeneca, Celgene, Gilead, Roche, Janssen, Novartis, Morphosys

Anna Maria Fink Grants: AstraZeneca, Celgene. Payment for lectures including service on speakers bureaus: AstraZeneca

Kirsten Fischer Honoraria: AbbVie, Roche. Travel grants: Roche

Barbara Eichhorst Research funding: AbbVie; AstraZeneca, BeiGene; Gilead, Janssen, Roche. Consulting fee or honorarium: AbbVie, AstraZeneca, BeiGene, MSD, Roche. Travel Support: BeiGene. Payment for lectures including service on speakers bureaus: AbbVie, AstraZeneca, BeiGene, MSD, Roche

Michael Hallek Hononraria (speaker's bureau and/or advisory/or advisory board): Roche, Gilead, Janssen, Bristol Myers Squibb, AbbVie, AstraZeneca. Grants: Roche, Gilead, Janssen, Bristol Myers Squibb, AbbVie, AstraZenec

Clemens-Martin Wendtner Consultancy: AbbVie, AstraZeneca, BeiGene, Janssen, Mundipharma, Roche

Additional information

Funding

This study was supported by research funding from F. Hoffmann-La Roche Ltd., Basel, Switzerland.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.